Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02339025 · ClinicalTrials.gov registry record

DoD-NCI TRICARE Feasibility Study

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status
93
Enrollment target

NCT02339025: Completed study, sponsored by National Cancer Institute (NCI).

NCT02339025 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 93 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02339025 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
93 participants
Enrollment target

Study Summary

Background: \- Researchers at the National Cancer Institute and the Department of Defense are trying to learn more about what causes cancer, heart disease, and other health problems. To do this, they gather data on risk factors and biological markers. They get these data from large groups of people in long-running studies. As these groups of people age, researchers must form new groups. TRICARE is a health insurance program for uniformed service members and their families. It is a major part of the Military Health System. Researchers hope to form a new study group from TRICARE members. This study will test if TRICARE members will take part in a research study. Objectives: \- To test if TRICARE members will take part in a research study. Eligibility: \- TRICARE members aged 35 74 with military primary care providers at Walter Reed National Military Medical Center. They must not have a prior diagnosis of cancer other than non-melanoma skin cancer. Design: * Participants will fill out a survey. It will ask about their risk factors for cancer and other chronic diseases. Their medical records will be reviewed. They will give a blood sample. * If a larger study is formed, then participants data will be used in the larger study. They may be asked to give more samples.

Trial Details

FieldValue
Enrollment Target 93 participants
Start Date 2018-08-18
Est. Completion 2019-09-23

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT02339025

The ClinicalTrials.gov registry entry for NCT02339025 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT02339025 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02339025 about?

NCT02339025 is a clinical study titled "DoD-NCI TRICARE Feasibility Study". Background: \- Researchers at the National Cancer Institute and the Department of Defense are trying to learn more about what causes cancer, heart disease, and other health problems. To do this, they gather data on risk factors and biological markers. They get these data from large groups of people...

What is the current status of trial NCT02339025?

This trial is currently completed. The enrollment target is 93 participants. The study started on 2018-08-18. Estimated completion is 2019-09-23.

Who is sponsoring clinical trial NCT02339025?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.